These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 27866773)

  • 1. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
    Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
    Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope.
    Chen S; Zheng D; Li C; Zhang W; Xu W; Liu X; Fang F; Chen Z
    Biomed Res Int; 2015; 2015():901817. PubMed ID: 25767809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
    To KK; Zhang AJ; Chan AS; Li C; Cai JP; Lau CC; Li CG; Jahan AS; Wu WL; Li L; Tsang AK; Chan KH; Chen H; Yuen KY
    Arch Virol; 2015 Mar; 160(3):777-86. PubMed ID: 25616843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant influenza H7 hemagglutinin containing CFLLC minidomain in the transmembrane domain showed enhanced cross-protection in mice.
    Wang Y; Zhang Y; Wu J; Lin Y; Wu Z; Wei Y; Wei X; Qin J; Xue C; Liu GD; Cao Y
    Virus Res; 2017 Oct; 242():16-23. PubMed ID: 28912070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response.
    Hodgins B; Yam KK; Winter K; Pillet S; Landry N; Ward BJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates.
    Kazaks A; Lu IN; Farinelle S; Ramirez A; Crescente V; Blaha B; Ogonah O; Mukhopadhyay T; de Obanos MP; Krimer A; Akopjana I; Bogans J; Ose V; Kirsteina A; Kazaka T; Stonehouse NJ; Rowlands DJ; Muller CP; Tars K; Rosenberg WM
    BMC Biotechnol; 2017 Nov; 17(1):79. PubMed ID: 29126399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.
    Pushko P; Pujanauski LM; Sun X; Pearce M; Hidajat R; Kort T; Schwartzman LM; Tretyakova I; Chunqing L; Taubenberger JK; Tumpey TM
    Vaccine; 2015 Sep; 33(38):4975-82. PubMed ID: 26207590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual N-linked glycosylation at residues 133 and 158 in the hemagglutinin are essential for the efficacy of H7N9 avian influenza virus like particle vaccine in chickens and mice.
    Wang Y; Li Q; Peng P; Zhang Q; Huang Y; Hu J; Hu Z; Liu X
    Vet Microbiol; 2024 Jul; 294():110108. PubMed ID: 38729093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.